JP2008521444A - 抗増殖活性を有するｍｄａ−７タンパク質変種 - Google Patents

抗増殖活性を有するｍｄａ−７タンパク質変種 Download PDF

Info

Publication number
JP2008521444A
JP2008521444A JP2007544547A JP2007544547A JP2008521444A JP 2008521444 A JP2008521444 A JP 2008521444A JP 2007544547 A JP2007544547 A JP 2007544547A JP 2007544547 A JP2007544547 A JP 2007544547A JP 2008521444 A JP2008521444 A JP 2008521444A
Authority
JP
Japan
Prior art keywords
polypeptide
mda
seq
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007544547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521444A5 (https=
Inventor
ポール ビー フィッシャー
パンカイ グプタ
Original Assignee
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク filed Critical ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
Publication of JP2008521444A publication Critical patent/JP2008521444A/ja
Publication of JP2008521444A5 publication Critical patent/JP2008521444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
JP2007544547A 2004-12-02 2005-12-02 抗増殖活性を有するｍｄａ−７タンパク質変種 Pending JP2008521444A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63242304P 2004-12-02 2004-12-02
PCT/US2005/043673 WO2006060680A2 (en) 2004-12-02 2005-12-02 Mda-7 protein variants having antiproliferative activity

Publications (2)

Publication Number Publication Date
JP2008521444A true JP2008521444A (ja) 2008-06-26
JP2008521444A5 JP2008521444A5 (https=) 2008-11-27

Family

ID=36565787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544547A Pending JP2008521444A (ja) 2004-12-02 2005-12-02 抗増殖活性を有するｍｄａ−７タンパク質変種

Country Status (5)

Country Link
US (2) US20080026410A1 (https=)
EP (1) EP1817060A4 (https=)
JP (1) JP2008521444A (https=)
CA (1) CA2589644A1 (https=)
WO (1) WO2006060680A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174354C (en) * 1993-10-27 2011-03-29 Paul B. Fisher Compositions of melanoma differentiation associated gene-7 (mda-7) in cancer diagnosis and treatment
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
JP2008527996A (ja) * 2005-01-25 2008-07-31 スカイ、ジェネティクス、インク 癌細胞のアポトーシスのための核酸
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
WO2008112470A1 (en) * 2007-03-09 2008-09-18 The Trustees Of Columbia University In The City Of New York Increased effectiveness of mda-7 with mdr-1 over-expression
CA2695809A1 (en) * 2007-08-08 2009-02-12 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactor for the production of interleukin-24 cytokine
US20110111432A1 (en) * 2008-03-12 2011-05-12 Manel Jordana Diagnostic method for peanut allergy
WO2009140572A2 (en) * 2008-05-15 2009-11-19 The Trustees Of Columbia University In The City Of New York Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7
GB2486871B (en) * 2010-08-02 2017-01-25 Kratos Analytical Ltd Methods and apparatuses for producing mass spectrum data
RU2542427C2 (ru) * 2013-03-12 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт теплофизики им. С.С. Кутателадзе Сибирского отделения Российской академии наук (ИТ СО РАН) Неинвазивный способ лазерной нанодиагностики онкологических заболеваний
EP3004153B1 (en) * 2013-06-04 2019-10-30 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
US9928408B2 (en) * 2016-06-17 2018-03-27 International Business Machines Corporation Signal processing
AU2019211256A1 (en) 2018-01-23 2020-08-06 Praveen BHOOPATHI MDA-7/IL secretory variants and methods of use
CA3118950C (en) * 2018-11-07 2024-01-09 Trustees Of Tufts College Atomic-force microscopy for identification of surfaces

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1994013307A1 (en) * 1992-12-11 1994-06-23 Steritech, Inc. Platelet activation and function
CA2174354C (en) * 1993-10-27 2011-03-29 Paul B. Fisher Compositions of melanoma differentiation associated gene-7 (mda-7) in cancer diagnosis and treatment
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6255071B1 (en) * 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US6780984B2 (en) * 2000-07-17 2004-08-24 Northwestern University Method for prognosing cancer and the proteins involved
AU2002220546A1 (en) * 2000-09-12 2002-03-26 Matthias Austen Nucleic acid molecules encoding a poly(adp-ribose) polymerase
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
AU2003274963A1 (en) * 2002-12-23 2004-07-29 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
US20040171108A1 (en) * 2003-02-07 2004-09-02 Fisher Paul B. Human excitatory amino acid transporter-2 gene promoter and uses thereof
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
AU2005236075A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers

Also Published As

Publication number Publication date
CA2589644A1 (en) 2006-06-08
WO2006060680A2 (en) 2006-06-08
EP1817060A2 (en) 2007-08-15
WO2006060680A3 (en) 2007-01-25
EP1817060A4 (en) 2008-05-07
US20080026410A1 (en) 2008-01-31
US20060292157A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
JP2008521444A (ja) 抗増殖活性を有するｍｄａ−７タンパク質変種
JP5824085B2 (ja) Ｊｎｋシグナル伝達経路に対する、細胞透過性のペプチド性阻害剤の種々の、疾病を治療するための使用
KR102578891B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2193143B1 (en) Compositions of humanized notch fusion proteins and methods of treatment
US20070293453A1 (en) Combinatorial Methods For Inducing Cancer Cell Death
AU2009200385A1 (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
JP2004511432A (ja) Ｅｇ−ｖｅｇｆ核酸及びポリペプチド及び使用方法
CA2365913C (en) Tumor necrosis factor receptor homologs and nucleic acids encoding the same
CN101918035B (zh) 针对抗癌药物抗性癌的具有抗癌药物增强作用的癌细胞死亡诱导剂
US20120214741A1 (en) Vdac1 compositions and methods of use thereof for regulating apoptosis
EP1856145B1 (en) Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US20060210536A1 (en) Methods and compositions for inhibiting stat signaling pathways
US7229822B1 (en) Melanoma differentation associated gene-5 and vectors and cells containing same
Peng et al. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes
US20080108067A1 (en) Cloning of the retinoic acid inducible gene-1 promoter and uses thereof
US20030049606A1 (en) Novel anti-viral and anti-proliferative agents derived from STAT1 transcription factor
WO2003031575A2 (en) A hybrid fusion protein transcription regulator to induce interferon target gene expression
KR100678523B1 (ko) Pro840 폴리펩티드 아고니스트 또는 길항제의 확인 방법
Sandey Elucidation of genomic structure, biological properties, and functional status of canine mda-7 and its receptors
AU2002331641A1 (en) Combinatorial methods for inducing cancer cell death
AU6930100A (en) P193 proteins and nucleic acids, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081009